Daily Newsletter

08 July 2024

Daily Newsletter

08 July 2024

Kerecis unveils Shield Spiral device for advanced wound care

Shield Spiral can be tailored to fit a variety of wound dimensions, offering flexibility and precision.

Archana Rani July 08 2024

Kerecis has expanded its silicone fish-skin combination product range by introducing Shield Spiral for wound management.

Shield Spiral's design ensures that it can be tailored to fit a variety of wound dimensions, offering flexibility and precision.

Capable of being reduced from 30mm to as small as 15mm, the grafts can maintain the same level of protection as other products in the Kerecis Shield range.

The combination of intact fish-skin graft and silicone features perforated fenestration marks, which are cut in a spiral pattern and enable easy customisation.

The Kerecis Shield product family, which includes Shield Adhesive and Shield Standard, is designed to manage various types of wounds such as pressure ulcers, diabetic foot ulcers, vascular ulcers and draining wounds.

Kerecis founder and CEO Fertram Sigurjonsson said: “At Kerecis, we continue to be inspired by the insights of the doctors that use the intact fish skin every day.

“The development of Shield Spiral is a direct result of feedback from doctors that asked for a product that could be shaped faster and easier to the size of smaller wounds.”

Earlier this year, Kerecis launched Shield Standard, a new fish-skin graft product with silicone backing.

Shield Standard has a borderless contact layer protecting the fish skin and is used in wound products to maintain a moist wound-healing environment.

Kerecis develops products from fish skin and fatty acids for tissue regeneration, cellular therapy, and protection.

Diabetes Assays Pipeline Market Overview

GlobalData's latest report provides a comprehensive understanding of the diabetes assays pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close